Conditions
Early Alzheimer’s Disease
Trial Purpose
Researchers want to know whether the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer’s disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech) and decision-making skills. It can limit a person’s ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.
The goals of this study are to learn:
* Whether MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD and damages brain cells. A placebo looks like the study treatment, but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment.
* About the safety of MK-2214 and whether people tolerate it
NATIONAL TRIAL REFERENCE NUMBER
NCT07033494
EU CT
2024-519190-19-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
50 - 85
Sex
All
About The Trial
Trial Phase
Trial Phase 2
Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.
Trial start and end dates
- Actual study start date 16 July 2025
- Estimated primary completion date 30 April 2029
- Estimated study completion date 30 April 2029
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about